PRO 140

PRO 140, developed by Progenics Pharmaceuticals, is a CCR5 monoclonal antibody that binds to the extracellular domain rather than the transmembrane pocket.

In a phase II dose-ranging study in patients who had not been on ARV therapy for at least three months and whose viral load was ≥5000 copies/ml, viral load decreased by nearly two logs in those taking a single 5 mg/kg dose of PRO 140. It remained one log below baseline level two to three weeks later.

No serious side-effects were reported.This trial established proof-of-concept for PRO 140 as a potent antiretroviral agent with extended activity after a single dose, with the advantage that maraviroc resistance does not seem to cause cross-resistance to PRO 140.1

References

  1. Jacobson JM et al. Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-Infected adults. J Infect Dis 98(9):1345-1352, 2008
This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.